

Andrew Spencer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9615898/publications.pdf>

Version: 2024-02-01

211
papers

13,209
citations

81900

39
h-index

23533

111
g-index

213
all docs

213
docs citations

213
times ranked

10667
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	10.7	1,866
2	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525
3	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
4	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	27.0	1,139
5	Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1125-1132.	1.6	1,090
6	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	10.7	723
7	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
8	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. <i>Journal of Clinical Oncology</i> , 2009, 27, 1788-1793.	1.6	315
9	International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 2347-2357.	1.6	307
10	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	1.4	294
11	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1617-1629.	10.7	289
12	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
13	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2020, 7, e456-e468.	4.6	244
14	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
15	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) <i>TJ ETQq1 1 0.784314 rgBT /Overlo</i>	10.7	219
16	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	13.7	187
17	Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. <i>Epigenetics</i> , 2014, 9, 1511-1520.	2.7	140
18	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020, 44, 100672.	5.7	135

#	ARTICLE	IF	CITATIONS
19	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. <i>Blood</i> , 2016, 128, 1834-1844.	1.4	127
20	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. <i>Blood</i> , 2014, 124, 2190-2195.	1.4	108
21	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 509-518.	0.4	91
22	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE [®] (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 28-29.	1.4	83
23	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	6.2	75
24	Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).. <i>Blood</i> , 2005, 106, 6-6.	1.4	70
25	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	7.2	69
26	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	3.5	68
27	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	7.1	67
28	Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2017, 215, 1684-1694.	4.0	61
29	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 42-43.	1.4	58
30	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2021, 39, 1139-1149.	1.6	57
31	Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. <i>Clinical Cancer Research</i> , 2016, 22, 4559-4566.	7.0	56
32	Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1961-1967.	2.0	56
33	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	7.2	55
34	Phase 1/1<sc>B</sc> trial of the heat shock protein 90 inhibitor <sc>NVP</sc>â€<sc>ALY</sc>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2015, 121, 2185-2192.	4.1	51
35	Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. <i>Leukemia</i> , 2019, 33, 2022-2033.	7.2	49
36	Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 255-258.	7.2	48

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	10.7	46
38	The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. <i>European Journal of Cancer</i> , 2015, 51, 1467-1475.	2.8	43
39	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	1.4	43
40	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020, 105, 468-477.	3.5	41
41	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	4.1	40
42	Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 26-27.	1.4	40
43	Î²-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1765-1778.	4.1	39
44	Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. <i>Cancer Biology and Medicine</i> , 2016, 13, 215-225.	3.0	36
45	Myeloma in the Real World: What Is Really Happening?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 133-144.e1.	0.4	34
46	Histone deacetylase (<sc>HDAC</sc>) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I <sc>HDAC</sc>. <i>British Journal of Haematology</i> , 2013, 162, 559-562.	2.5	33
47	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	17.0	32
48	Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2008, 112, 958-958.	1.4	32
49	Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 497-505.	3.0	30
50	Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1858.	4.1	28
51	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 302-302.	1.4	28
52	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	2.5	27
53	Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. <i>BMC Medical Research Methodology</i> , 2016, 16, 151.	3.1	25
54	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25

#	ARTICLE	IF	CITATIONS
55	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. <i>Blood</i> , 2019, 134, 142-142.	1.4	25
56	First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).. <i>Blood</i> , 2006, 108, 58-58.	1.4	22
57	Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1067-1076.	2.3	21
58	Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients. <i>Cancers</i> , 2019, 11, 887.	3.7	20
59	Treatment of invasive IMP4<i>Enterobacter cloacae</i> infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review. <i>Transplant Infectious Disease</i> , 2021, 23, e13510.	1.7	20
60	The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. <i>Oncotarget</i> , 2017, 8, 52269-52280.	1.8	20
61	Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. <i>Haematologica</i> , 2018, 103, e25-e28.	3.5	19
62	A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 2774-2774.	1.4	19
63	Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders. <i>Leukemia</i> , 2021, 35, 2771-2783.	7.2	17
64	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor. <i>Blood</i> , 2018, 132, 3272-3272.	1.4	17
65	DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients. <i>Cancers</i> , 2019, 11, 917.	3.7	16
66	Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 536-546.	2.5	16
67	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. <i>Blood</i> , 2011, 118, 811-811.	1.4	16
68	Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.. <i>Blood</i> , 2006, 108, 3554-3554.	1.4	14
69	Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2015, 55, 2709-2713.	1.6	13
70	Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 1506.	4.8	13
71	Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). <i>Leukemia and Lymphoma</i> , 2019, 60, 2143-2151.	1.3	13
72	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e415-e424.	0.4	13

#	ARTICLE	IF	CITATIONS
73	Human myeloma cell- and plasma-derived extracellular vesicles contribute to functional regulation of stromal cells. <i>Proteomics</i> , 2021, 21, e2000119.	2.2	13
74	Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3551-3551.	1.4	13
75	A Phase I/II Study of BHQ880, a Novel Osteoblast Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).. <i>Blood</i> , 2009, 114, 750-750.	1.4	13
76	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (Dvd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA4-LBA4.	1.6	13
77	Azacitidine Down-Regulates Both IL-6 Signalling and NFkB Activity in Human Myeloma Cells.. <i>Blood</i> , 2006, 108, 3441-3441.	1.4	13
78	An Evidence-Based Approach to Myeloma Bone Disease. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 109-118.	2.3	12
79	DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2842-2846.	1.3	12
80	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e510-e520.	0.4	12
81	An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 3604-3604.	1.4	11
82	Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2007, 110, 907-907.	1.4	11
83	The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma. <i>Cells</i> , 2021, 10, 3464.	4.1	11
84	Comparison of the probability of target attainment of anidulafungin against <i>Candida</i> spp. in patients with acute leukaemia. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 450-457.	2.5	10
85	Analysis of Circulating Tumor DNA. <i>Methods in Molecular Biology</i> , 2018, 1792, 129-145.	0.9	10
86	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. <i>British Journal of Haematology</i> , 2021, 193, 561-569.	2.5	10
87	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765.	0.4	10
88	Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. <i>The Hematology Journal</i> , 2004, 5, 216-221.	1.4	10
89	A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 5031-5031.	1.4	10
90	Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study. <i>Blood</i> , 2011, 118, 1856-1856.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 408-408.	1.4	10
92	Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. <i>BMC Clinical Pharmacology</i> , 2008, 8, 2.	2.5	9
93	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Blood</i> , 2018, 132, 301-301.	1.4	9
94	Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation. <i>Cancer Treatment Reviews</i> , 2016, 50, 200-204.	7.7	8
95	Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma. <i>Methods in Molecular Biology</i> , 2021, 2261, 151-191.	0.9	8
96	A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. <i>Haematologica</i> , 2015, 100, e60-e62.	3.5	7
97	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <i>Bone Marrow Transplantation</i> , 2021, 56, 2533-2543.	2.4	7
98	Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-15.	1.4	7
99	Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.. <i>Blood</i> , 2009, 114, 2898-2898.	1.4	7
100	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. <i>Blood</i> , 2011, 118, 2599-2599.	1.4	7
101	Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4220-4220.	1.4	7
102	Circulating tumour DNA analysis in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 90610-90611.	1.8	7
103	Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β -Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo. <i>Cancers</i> , 2022, 14, 840.	3.7	7
104	Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomes. <i>Supportive Care in Cancer</i> , 2018, 26, 947-955.	2.2	6
105	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2252-2261.	2.0	6
106	Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (<sc>MyPROMPT</sc>) – a pilot randomized controlled trial. <i>American Journal of Hematology</i> , 2020, 95, E178-E181.	4.1	6
107	Australia and New Zealand Transplant and Cellular Therapies <sc>COVID-19</sc> vaccination consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 1321-1323.	0.8	6
108	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. <i>Blood</i> , 2010, 116, 3299-3299.	1.4	6

#	ARTICLE	IF	CITATIONS
109	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. <i>Blood</i> , 2016, 128, 3326-3326.	1.4	6
110	A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103606.	4.4	6
111	Tumour Kinetics in Multiple Myeloma Before, During, and After Treatment. <i>Leukemia and Lymphoma</i> , 2001, 40, 373-384.	1.3	5
112	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e247-e255.	2.0	5
113	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16 trial. <i>British Journal of Haematology</i> , 2021, 194, 580-586.	2.5	5
114	Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8609-TPS8609.	1.6	5
115	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA4-LBA4.	1.6	5
116	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 820768.	2.8	5
117	Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". <i>Haematologica</i> , 2015, 100, e379-e379.	3.5	4
118	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	1.8	4
119	Brick plots: an intuitive platform for visualizing multiparametric immunophenotyped cell clusters. <i>BMC Bioinformatics</i> , 2020, 21, 145.	2.6	4
120	Phase II trial of single-agent panobinostat consolidation improves responses after suboptimal transplant outcomes in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 160-170.	2.5	4
121	Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 718502.	2.8	4
122	Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.. <i>Blood</i> , 2009, 114, 1876-1876.	1.4	4
123	Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8036-8036.	1.6	4
124	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. <i>Blood</i> , 2018, 132, 3289-3289.	1.4	4
125	Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8052-8052.	1.6	4
126	Myeloma of the central nervous system – an ongoing conundrum!. <i>Leukemia and Lymphoma</i> , 2016, 57, 1505-1506.	1.3	3

#	ARTICLE	IF	CITATIONS
127	Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e470-e477.	0.4	3
128	Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement. <i>Internal Medicine Journal</i> , 2020, 50, 774-775.	0.8	3
129	Important factors in implementation of lineage-specific chimerism analysis for routine use. <i>Bone Marrow Transplantation</i> , 2021, 56, 946-948.	2.4	3
130	Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1510-1510.	1.4	3
131	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. <i>Blood</i> , 2008, 112, 3701-3701.	1.4	3
132	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , 2016, 128, 2980-2980.	1.4	3
133	Safety and efficacy of daratumumab-based regimens in elderly (>75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8033-8033.	1.6	3
134	Carfilzomib 56 mg/m ² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DvD): a matching-adjusted indirect treatment comparison. <i>Leukemia and Lymphoma</i> , 2022, 63, 1887-1896.	1.3	3
135	The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. <i>Bone Marrow Transplantation</i> , 2022, 57, 982-989.	2.4	3
136	Reply to S.M. Sorscher et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 2736-2737.	1.6	2
137	TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. <i>Leukemia and Lymphoma</i> , 2021, 62, 337-347.	1.3	2
138	Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1116-1125.	2.4	2
139	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. <i>European Journal of Haematology</i> , 2021, 107, 497-499.	2.2	2
140	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). <i>Leukemia and Lymphoma</i> , 2021, 62, 2981-2991.	1.3	2
141	The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.. <i>Blood</i> , 2005, 106, 5108-5108.	1.4	2
142	Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.. <i>Blood</i> , 2007, 110, 4941-4941.	1.4	2
143	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.. <i>Blood</i> , 2009, 114, 2693-2693.	1.4	2
144	Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. <i>Blood</i> , 2013, 122, 2939-2939.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.. Journal of Clinical Oncology, 2013, 31, 8589-8589.	1.6	2
146	Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality. Blood, 2013, 122, 2128-2128.	1.4	2
147	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 11-12.	1.4	2
148	The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood, 2020, 136, 30-31.	1.4	2
149	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2022, 107, 774-775.	3.5	2
150	No longer the poor relations. Blood, 2010, 116, 3685-3686.	1.4	1
151	Panobinostat (LBH589) in combination with the β -catenin inhibitor Tegavivint (BC2059) exerts significant anti-myeloma activity both in vitro and in vivo. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e137.	0.4	1
152	Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC) Tj ETQqO O1rgBT /Overlock 10		
153	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2020, 136, 4-5.	1.4	1
154	Laboratory Tumor Lysis Syndrome Complicating LBH589 Therapy in a Patient with Acute Myeloid Leukemia.. Blood, 2006, 108, 4554-4554.	1.4	1
155	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib \pm Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. Blood, 2007, 110, 2735-2735.	1.4	1
156	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study. Blood, 2011, 118, 1529-1529.	1.4	1
157	Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival. Blood, 2012, 120, 4065-4065.	1.4	1
158	Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide. Blood, 2015, 126, 3033-3033.	1.4	1
159	Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre. Blood, 2015, 126, 5543-5543.	1.4	1
160	A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with β 2m ⁺ CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy. Blood, 2016, 128, 4515-4515.	1.4	1
161	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. Journal of Clinical Oncology, 2019, 37, 8040-8040.	1.6	1
162	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.8	1

#	ARTICLE	IF	CITATIONS
163	A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.. Blood, 2004, 104, 4597-4597.	1.4	1
164	Flavopiridol Decreases the Level of p21 and Induces Apoptosis in Human Myeloma Cell Lines.. Blood, 2005, 106, 5188-5188.	1.4	1
165	Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. Blood, 2007, 110, 2740-2740.	1.4	1
166	A New Generation XIAP Inhibitor Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics.. Blood, 2007, 110, 4787-4787.	1.4	1
167	Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study. Blood, 2010, 116, 3301-3301.	1.4	1
168	A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,. Blood, 2011, 118, 3625-3625.	1.4	1
169	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 3448-3448.	1.4	1
170	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2021, 138, 2728-2728.	1.4	1
171	An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation. Blood, 2020, 136, 36-37.	1.4	1
172	Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DvD); A Matching-Adjusted Indirect Treatment Comparison. Blood, 2020, 136, 8-9.	1.4	1
173	The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma. Bone Marrow Transplantation, 2022, 57, 1001-1003.	2.4	1
174	Reply to M. Cavo. Journal of Clinical Oncology, 2009, 27, e188-e188.	1.6	0
175	High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission. Bone Marrow Transplantation, 2020, 55, 2207-2210.	2.4	0
176	Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML). Leukemia and Lymphoma, 2021, 62, 489-491.	1.3	0
177	Planned withdrawal of dexamethasone after pomalidomide low dose dexamethasone induction for lenalidomide refractory multiple myeloma (ALLG MM14). Haematologica, 2021, , .	3.5	0
178	Fluvastatin-Zometa (FluZom) as A Possible Therapeutic Approach to Plasma Cell Disorders.. Blood, 2004, 104, 4937-4937.	1.4	0
179	Azacytidine Suppressors Autocrine IL-6 Secretion and Demonstrates In Vitro and In Vivo Activity Against Multiple Myeloma.. Blood, 2005, 106, 1566-1566.	1.4	0
180	An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.. Blood, 2005, 106, 3336-3336.	1.4	0

#	ARTICLE	IF	CITATIONS
181	PKC412 Induces Apoptosis in Human Multiple Myeloma Cell Lines and Primary Myeloma Cells.. Blood, 2005, 106, 1587-1587.	1.4	0
182	Gene Expression Profiling in Multiple Myeloma Cells Treated with the Novel Anti-Myeloma Agents Zoledronate and Fluvastatin.. Blood, 2005, 106, 5078-5078.	1.4	0
183	The Focal Adhesion Kinase (FAK) Inhibitor TAE226 Exhibits In Vitro and In Vivo Activity Against Multiple Myeloma.. Blood, 2006, 108, 844-844.	1.4	0
184	Modulation of the Mitochondrial (Type 2) Apoptotic Pathway Can Enhance Apo2L/TRAIL - Mediated Killing of Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3447-3447.	1.4	0
185	Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.. Blood, 2006, 108, 2450-2450.	1.4	0
186	A Newly Developed IAP Inhibitor (IAPi) Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics. Blood, 2008, 112, 5156-5156.	1.4	0
187	MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells.. Blood, 2009, 114, 1846-1846.	1.4	0
188	A Novel Orally Bioavailable Heat Shock Protein 90 Inhibitor Induces Apoptosis and Synergises with Bortezomib in Human Multiple Myeloma.. Blood, 2009, 114, 1838-1838.	1.4	0
189	Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse., Blood, 2011, 118, 3631-3631.	1.4	0
190	A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998â€“2008., Blood, 2011, 118, 4143-4143.	1.4	0
191	Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor. Blood, 2012, 120, 1842-1842.	1.4	0
192	CD45-Ve but Not CD45+Ve U266 Myeloma Cells Demonstrate an Active Epithelial to Mesenchymal Transition (EMT) Transcriptional Programme. Blood, 2012, 120, 3988-3988.	1.4	0
193	The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells. Blood, 2012, 120, 4012-4012.	1.4	0
194	BC2059: An Orally Bioavailable Î²-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma. Blood, 2013, 122, 1920-1920.	1.4	0
195	Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments. Blood, 2014, 124, 2103-2103.	1.4	0
196	The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study. Blood, 2015, 126, 4312-4312.	1.4	0
197	In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma. Blood, 2015, 126, 1816-1816.	1.4	0
198	Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblastic Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia. Blood, 2015, 126, 2030-2030.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors. Blood, 2015, 126, 5375-5375.	1.4	0
200	Overcoming Innate Resistance to a Beta-Catenin Inhibitor-BC2059- By Manipulating Autophagy in Multiple Myeloma. Blood, 2016, 128, 5669-5669.	1.4	0
201	TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma. Blood, 2016, 128, 4461-4461.	1.4	0
202	Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood, 2021, 138, 4757-4757.	1.4	0
203	Targeting Bclxl Mitigates Mcl1 Chemoresistance in Multiple Myeloma. Blood, 2021, 138, 2656-2656.	1.4	0
204	Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 18-19.	1.4	0
205	Peripheral Blood CD34+ Donor Chimerism Is Superior to CD3+ Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Blood, 2020, 136, 47-48.	1.4	0
206	Malignant Clonal Cell Proliferation in Multiple Myeloma and the Hypercoagulable State. Blood, 2020, 136, 23-24.	1.4	0
207	Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial). Blood, 2020, 136, 34-35.	1.4	0
208	Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor. Blood, 2020, 136, 38-41.	1.4	0
209	Māori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	0
210	Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning. Bone Marrow Transplantation, 2022, , .	2.4	0
211	Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy.. Journal of Clinical Oncology, 2022, 40, 8037-8037.	1.6	0